|
Market Closed -
Nasdaq
20:00:00 30/10/2026 GMT
|
5-day change | 1st Jan Change | ||
| 558.88 USD | +3.50% |
|
+6.67% | +23.28% |
| 09:44am | Stock Futures Higher, Oil Lower as Investors Return to Risk | DJ |
| 10-30 | UK Healthcare Regulator OKs Vertex Pharmaceuticals' Casgevy Gene Therapy for Children From Age Five | MT |
| Market Cap | 142B 127B 117B 106B 198B 13,450B 201B 1,392B 559B 7,075B 532B 520B 22,313B | P/E 2026 * |
33.2x | P/E 2027 * | 30.1x |
|---|---|---|---|---|---|
| Enterprise Value | 134B 120B 110B 99.99B 187B 12,719B 190B 1,316B 528B 6,690B 503B 492B 21,099B | EV / Sales 2026 * |
10.1x | EV / Sales 2027 * | 9.02x |
| Free-Float |
99.79% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| VRTX | Delayed | |
CBOE
| VRTX | Real-time | |
|
Tradegate
| VX1 | Real-time | |
|
Xetra
| VX1 | Delayed | |
|
Borsa Italiana
| 1VRTX | End-of-day quote | |
|
Boerse Muenchen
| VX1 | Real-time | |
|
Mexican S.E.
| VRTX * | End-of-day quote | |
|
London S.E.
| 0QZU | Delayed | |
|
Deutsche Boerse AG
| VX1 | Delayed | |
|
Wiener Boerse
| VRTX | End-of-day quote | |
|
Börse Stuttgart
| VX1 | Delayed | |
|
CBOE
| 0QZU | Real-time | |
|
CBOE
| Real-time |
Last Transcript: Vertex Pharmaceuticals Incorporated
| 1 day | +3.50% | ||
| 1 week | +6.67% | ||
| 1 month | +10.29% | ||
| 3 months | +17.14% | ||
| 6 months | +31.84% | ||
| Current year | +23.28% |
| 1 week | 509.2 |  | 563.8 |
| 1 month | 484.08 | | 563.8 |
| Current year | 412.27 | | 563.8 |
| 1 year | 403.16 | | 563.8 |
| 3 years | 341.9 | | 563.8 |
| 5 years | 179.96 | | 563.8 |
| 10 years | 71.46 | | 563.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 31/03/2020 | |
Charles Wagner
DFI | Director of Finance/CFO | 57 | 09/04/2019 |
Agam Upadhyay
CTO | Chief Tech/Sci/R&D Officer | - | 30/06/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Bruce Sachs
BRD | Director/Board Member | 66 | 31/12/1997 |
Jeffrey Leiden
CHM | Chairman | 70 | 30/04/2012 |
Sangeeta Bhatia
BRD | Director/Board Member | 57 | 17/06/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 28/08/26 | Free | Controller/Auditor | 5,000 | 0.0020% | ||
| 27/08/26 | Don | Director | -6,000 | 0.0024% | ||
| 21/07/26 | Free | General Counsel | 8,251 | 0.0033% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.50% | +6.67% | +31.33% | +51.32% | 142B | |
| +3.19% | +11.31% | +64.28% | +155.66% | 1,263B | |
| -0.73% | +3.56% | +44.65% | +83.74% | 658B | |
| +1.41% | +3.24% | +35.25% | +106.98% | 521B | |
| -1.34% | +0.35% | +53.33% | +67.08% | 391B | |
| +2.18% | +2.93% | +73.90% | +45.38% | 369B | |
| -1.21% | +3.50% | +32.60% | +55.85% | 307B | |
| -0.44% | +7.89% | +12.16% | +33.84% | 290B | |
| +1.15% | +6.09% | +56.15% | +78.66% | 252B | |
| +3.06% | +9.38% | +42.48% | +112.84% | 212B | |
| Average | +1.08% | +5.98% | +44.61% | +79.13% | 440.36B | |
| Weighted average by Cap. | +1.25% | +6.60% | +49.53% | +97.25% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 13.28B 11.89B 10.94B 9.91B 18.53B 1,261B 18.88B 130B 52.38B 663B 49.84B 48.78B 2,092B | 14.6B 13.08B 12.03B 10.9B 20.37B 1,386B 20.75B 143B 57.58B 729B 54.8B 53.63B 2,300B |
| Net income | 4.38B 3.92B 3.6B 3.27B 6.11B 415B 6.22B 42.99B 17.26B 219B 16.42B 16.07B 689B | 4.87B 4.36B 4.01B 3.63B 6.79B 462B 6.92B 47.81B 19.19B 243B 18.27B 17.88B 767B |
| Net Debt | -7.7B -6.9B -6.35B -5.75B -10.75B -731B -10.95B -75.68B -30.38B -385B -28.91B -28.3B -1,213B | -10.02B -8.97B -8.25B -7.48B -13.98B -951B -14.24B -98.41B -39.5B -500B -37.59B -36.79B -1,578B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/10/26 | US$558.88 | +3.50% | 3,030,027 |
| 29/10/26 | US$540.00 | +1.95% | 1,542,075 |
| 28/10/26 | US$529.69 | +1.66% | 1,284,581 |
| 27/10/26 | US$521.03 | +0.68% | 1,019,888 |
| 26/10/26 | US$517.49 | -1.23% | 1,189,035 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VRTX Stock
Select your edition
All financial news and data tailored to specific country editions
